dorsaVi receives $350,000 Victorian Government Future Industries Manufacturing Grant; plans to improve local manufacturing facilities fast-tracked
CLICK HERE TO CONTACT dorsaVi

Melbourne, Australia.  29 September 2016.  dorsaVi (ASX:DVL) is pleased to announce they have received a Victorian Government Future Industries Manufacturing grant of $350,000. The Future Industries Manufacturing Program offers funding to Victorian-based companies to implement new manufacturing technologies and processes to facilitate growth.

dorsaVi Chief Executive Officer Andrew Ronchi said the grant would be used to help fund the new manufacturing facilities, equipment and staff in its Jolimont premises that are required to bring the next generation of its wearable medical-grade sensors to the market. The grant will allow dorsaVi to complete the facility sooner than originally anticipated. This initiative will greatly assist the scale and speed of manufacturing of the world-leading wearables.

The new facility will incorporate cutting-edge technologies which will reduce manufacturing timelines, automate manual processes, improve stock control and product traceability, and overall manufacturing costs. This funding ultimately ensures that dorsaVi is able to significantly reduce the cost of goods whilst maintaining the high level of quality required for its FDA cleared medical device. 

– END –

Melbourne, Australia.  29 September 2016.  dorsaVi (ASX:DVL) is pleased to announce they have received a Victorian Government Future Industries Manufacturing grant of $350,000. The Future Industries Manufacturing Program offers funding to Victorian-based companies to implement new manufacturing technologies and processes to facilitate growth.

dorsaVi Chief Executive Officer Andrew Ronchi said the grant would be used to help fund the new manufacturing facilities, equipment and staff in its Jolimont premises that are required to bring the next generation of its wearable medical-grade sensors to the market. The grant will allow dorsaVi to complete the facility sooner than originally anticipated. This initiative will greatly assist the scale and speed of manufacturing of the world-leading wearables.

The new facility will incorporate cutting-edge technologies which will reduce manufacturing timelines, automate manual processes, improve stock control and product traceability, and overall manufacturing costs. This funding ultimately ensures that dorsaVi is able to significantly reduce the cost of goods whilst maintaining the high level of quality required for its FDA cleared medical device. 

– END –

Request more information about our technology

CONTACT ME FOR MORE INFORMATION

Randomised Controlled Trial with dorsaVi technology finds back pain patients monitored and treated using dorsaVi's sensors had significant, sustained improvements in pain and function.

Recent news: What's happening at dorsaVi 

ViPerform and the NFL: How Loren Landow uses objective data to assess risk of injury

Fix the following errors:
Hide